Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226
Nai-Cen ZHOU; Bao-Lan LIU; Mei-Ying QI; Bo XU; Xin LIU.
Journal of Experimental Hematology
; (6): 1331-1335, 2014.
ArtÃculo en Zh | WPRIM | ID: wpr-340503
Documentos relacionados
[Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226].
Quantification of Sorafenib in Human Serum by Competitive Enzyme-Linked Immunosorbent Assay.
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.
Fabrication of Ag-CaCO<sub>3</sub> Nanocomposites for SERS Detection of Forchlorfenuron.
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
New knowledge of the mechanisms of sorafenib resistance in liver cancer.
Ca<sup>2+</sup>-Dependent Effects of the Selenium-Sorafenib Nanocomplex on Glioblastoma Cells and Astrocytes of the Cerebral Cortex: Anticancer Agent and Cytoprotector.
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.